Search: onr:"swepub:oai:lup.lub.lu.se:b592dc41-2d80-4b23-88dc-ed18538a89e7" >
A novel food-based ...
A novel food-based negative oral contrast agent compared with two conventional oral contrast agents in abdominal CT : a three-arm parallel blinded randomised controlled single-centre trial
-
- Leander, Peter (author)
- Perituskliniken AB
-
- Stathis, Georgios (author)
- Skåne University Hospital,Lund University
-
- Casal-Dujat, Lucia (author)
- Lument AB
-
show more...
-
- Boman, Karolina (author)
- Skåne University Hospital
-
- Adnerhill, Ingvar (author)
- Lund University,Lunds universitet,Diagnostisk radiologi, Malmö,Forskargrupper vid Lunds universitet,Radiology Diagnostics, Malmö,Lund University Research Groups,Skåne University Hospital
-
- Marsal, Jan (author)
- Lund University,Lunds universitet,Gastro,Forskargrupper vid Lunds universitet,Lund University Research Groups,Skåne University Hospital
-
- Böök, Olof (author)
- Lument AB
-
- Fork, Thomas (author)
- Lund University,Lunds universitet,Diagnostisk radiologi, Malmö,Forskargrupper vid Lunds universitet,Radiology Diagnostics, Malmö,Lund University Research Groups,Skåne University Hospital,Lument AB
-
show less...
-
(creator_code:org_t)
- 2022-04-05
- 2022
- English.
-
In: European Radiology Experimental. - : Springer Science and Business Media LLC. - 2509-9280. ; 6:1
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background: A negative oral contrast agent (OCA) has been long sought for, to better delineate the bowel and visualise surrounding structures. Lumentin® 44 (L44) is a new OCA formulated to fill the entire small bowel. The aim of this study was to compare L44 with positive and neutral conventional OCA in abdominal computed tomography (CT). Methods: Forty-five oncologic patients were randomised to receive either L44 or one of the two comparators (MoviPrep® or diluted Omnipaque®). Abdominal CT examinations with intravenous contrast agent were acquired according to standard protocols. The studies were read independently by two senior radiologists. Results: The mean intraluminal Hounsfield units (HU)-values of regions-of-interest (ROIs) for each subsegment of small bowel and treatment group were -404.0 HU for L44, 166.1 HU for Omnipaque®, and 16.7 HU for MoviPrep® (L44 versus Omnipaque, p < 0.001: L44 versus MoviPrep p < 0.001; Omnipaque versus MoviPrep, p = 0.003). Adverse events, only mild, using L44 were numerically fewer than for using conventional oral contrast agents. Visualisation of abdominal structures beyond the small bowel was similar to the comparators. Conclusions: L44 is a negative OCA with luminal radiodensity at approximately -400 HU creating a unique small bowel appearance on CT scans. The high bowel wall-to-lumen contrast may enable improved visualisation in a range of pathologic conditions. L44 showed a good safety profile and was well accepted by patients studied. Trial registration: EudraCT (2017-002368-42) and in ClinicalTrials.gov (NCT03326518).
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Keyword
- Contrast media
- Intestine (small)
- Iohexol
- MoviPrep
- Tomography (x-ray computed)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database